

Ayuda Estudios Clínicos AECC 2023

Adjudicatarios

Dr. Julio Delgado

Fundació Clínic per a la Recerca
Biomèdica-IDIBAPS

First-in-human, open-label, prospective, non-randomized clinical trial to evaluate the safety of ARI-HER2 (HER2BBz CAR-T cells) in subject: with relapse or refractory HER2-positive metastatic breast cancer

Dra. Irene Braña

Vall d'Hebron Instituto de Oncología
(VHIO)

PROLoNg: Pembrolizumab and Radiotherapy for OLigometastatic squamous cell carcinoma of the head and Neck: a randomized phase III study